drugset / Trial / NCT00935493

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

NCT00935493

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.

Timeline

Start
2009-06
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Guanfacine Small molecule 0.1 mg Oral
Subject Guanfacine Small molecule 0.5 mg Oral

Indications

No indication recorded.